Semaglutide

Type 2 Diabetes Management

Semaglutide is prescribed to help adults with type 2 diabetes control their blood sugar levels. It is intended to be used in combination with a healthy diet and regular physical activity. It is not used to treat type 1 diabetes or diabetic ketoacidosis.

Cardiovascular Risk Reduction

This medication is used to lower the risk of major cardiovascular events, such as heart attack, stroke, or death, in specific groups of people:

• Adults with type 2 diabetes and established heart or blood vessel disease.
• Adults with known heart disease who also have obesity or are overweight.

Chronic Weight Management

Semaglutide is used for long-term weight management in adults who meet specific criteria. It is typically prescribed for:

• Adults with obesity (a body mass index of 30 or higher).
• Adults who are overweight (a body mass index of 27 or higher) and have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

When used for weight management, it is meant to be part of a comprehensive plan that includes a reduced-calorie diet and increased physical activity.

Mechanism of Action

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It works by acting like the GLP-1 hormone that is naturally released in the gastrointestinal tract after eating.

Blood Sugar Regulation

This medication helps manage blood sugar in several ways:

• Insulin Release: It signals the pancreas to release more insulin when blood sugar levels are high.
• Sugar Production: It helps prevent the liver from making and releasing too much sugar into the bloodstream.

Digestion and Appetite

Semaglutide also affects how the body processes food and perceives hunger:

• Slower Digestion: It slows down the speed at which food leaves the stomach, which can help people feel full for a longer period after eating.
• Appetite Control: It targets areas of the brain that regulate appetite and food intake, helping to reduce feelings of hunger and cravings.

By combining these effects, the medication helps lower blood sugar levels and can assist with weight management in certain individuals. It is also used to reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults with certain health conditions.

Common Side Effects

The most frequent side effects of semaglutide are related to the digestive system. These symptoms often occur when starting the medication or when the dose is increased. Common side effects include:

• Nausea and vomiting
• Diarrhea or constipation
• Stomach pain or bloating
• Heartburn, burping, or gas
• Fatigue
• Headache
• Dizziness

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider if you experience:

• Pancreatitis: Severe pain in the upper stomach that may spread to the back, with or without vomiting.
• Gallbladder problems: Symptoms such as upper stomach pain, fever, or yellowing of the skin or eyes (jaundice).
• Kidney issues: Changes in urination or swelling in the legs and ankles, which may be related to dehydration from vomiting or diarrhea.
• Vision changes: New or worsening blurred vision or other changes in sight, particularly in patients with diabetic retinopathy.
• Low blood sugar (hypoglycemia): Symptoms include shakiness, sweating, confusion, and rapid heartbeat, especially if used with other diabetes medications like insulin or sulfonylureas.
• Serious allergic reactions: Swelling of the face, lips, or throat, difficulty breathing, or severe rash.

Patients using the injectable form of the medication may also experience redness, itching, or pain at the site of the injection.

Boxed Warning: Thyroid C-Cell Tumors

In animal studies, semaglutide caused thyroid C-cell tumors. It is not known whether semaglutide causes these tumors, including medullary thyroid carcinoma (MTC), in humans. This medication is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis

Acute and chronic pancreatitis have been reported in patients using GLP-1 receptor agonists. If pancreatitis is suspected, the medication is typically discontinued. Patients with a history of pancreatitis may be at higher risk.

Diabetic Retinopathy

In clinical trials involving patients with type 2 diabetes, rapid improvement in blood sugar control has been associated with a temporary worsening of diabetic retinopathy. Monitoring by an eye specialist is recommended for patients with a history of this condition.

Kidney and Gallbladder Issues

• Kidney Injury: Severe gastrointestinal side effects, such as nausea, vomiting, and diarrhea, can lead to dehydration. This dehydration may cause acute kidney injury or worsening of chronic kidney failure.
• Gallbladder Problems: Use of semaglutide is associated with an increased risk of gallbladder-related events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).

Hypoglycemia

The risk of low blood sugar (hypoglycemia) increases when semaglutide is used in combination with insulin or insulin secretagogues, such as sulfonylureas. Adjustments to the dosage of concurrent medications may be necessary to reduce this risk.

Hypersensitivity

Serious allergic reactions, including anaphylaxis and angioedema, have occurred. If a serious hypersensitivity reaction is suspected, the medication must be stopped immediately and medical attention sought.

Compounded Semaglutide

The FDA has expressed concerns regarding unapproved compounded versions of semaglutide. Some compounded products may contain salt forms, such as semaglutide sodium or semaglutide acetate, which have not been evaluated for safety or effectiveness in the same way as the approved versions.

Suicidal Behavior and Ideation

Monitoring for the emergence or worsening of depression, suicidal thoughts, or any unusual changes in mood or behavior is recommended, particularly for patients using the medication for chronic weight management.

Pregnancy Considerations

The use of semaglutide during pregnancy is generally not recommended. Data from animal studies suggest that the medication may cause fetal harm, including potential pregnancy loss or developmental issues. Because semaglutide remains in the body for several weeks after the last dose, healthcare providers typically advise patients to discontinue the medication at least two months before a planned pregnancy to ensure it is cleared from the system.

Breastfeeding Considerations

It is currently unknown whether semaglutide passes into human breast milk or how it might affect a nursing infant. Because the risks to a breastfeeding child are not fully understood, it is important to discuss the benefits and potential risks with a healthcare professional. They can help determine if you should continue the medication or seek alternative treatments while breastfeeding.

Consulting Your Healthcare Provider

If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss your options with a medical professional. Important points for discussion include:

• The potential risks to the fetus or nursing infant based on current evidence.
• The timing for stopping the medication before attempting to conceive.
• Alternative methods for managing blood sugar levels or weight during pregnancy and the postpartum period.

Available Forms

Semaglutide is available in two primary delivery methods:

• Oral Tablet: This form is taken by mouth.
• Subcutaneous Injection: This form is a liquid solution injected under the skin, typically in the thigh, abdomen, or upper arm. It is provided in pre-filled pens.

Strengths

The medication is available in multiple strengths. Healthcare providers typically start patients on a low dose and gradually increase the strength over several weeks. The specific strengths and delivery schedules vary based on the condition being treated, such as type 2 diabetes or chronic weight management.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved semaglutide for several specific uses:

• Type 2 Diabetes: It is approved to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise.
• Cardiovascular Risk Reduction: It is approved to reduce the risk of major cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes and known heart disease.
• Weight Management: It is approved for chronic weight management in adults and some pediatric patients with obesity, or those who are overweight with at least one weight-related condition (such as high blood pressure or high cholesterol).
• Heart Disease in Obesity: It is also approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are either obese or overweight.

Boxed Warning

Semaglutide carries a boxed warning regarding the risk of thyroid C-cell tumors. In animal studies, semaglutide caused thyroid tumors, though it is unknown if it causes these tumors in humans. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use this medication.

Regulatory Concerns and Safety Communications

The FDA has issued communications regarding the use of unapproved or compounded versions of GLP-1 medications, including semaglutide. Compounded drugs are not FDA-approved, and the agency has expressed concerns about the safety and effectiveness of these versions, particularly those using salt forms like semaglutide sodium or semaglutide acetate.

Additionally, the FDA monitors marketing practices and has issued warning letters to manufacturers regarding the promotion of these drugs to ensure that risk information is clearly communicated to the public.

How It Works for Weight Loss

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. It mimics a naturally occurring hormone in the body that helps regulate appetite and food intake. By acting on the brain's hunger centers, it helps people feel fuller sooner and reduces overall calorie consumption.

Approved Uses

Semaglutide is approved for chronic weight management in specific populations when used alongside a reduced-calorie diet and increased physical activity. These populations include:

• Adults with obesity (a body mass index of 30 or greater).
• Adults with overweight (a body mass index of 27 or greater) who also have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
• Children aged 12 years and older who meet specific weight criteria for their age and sex.

Cardiovascular Benefits

In addition to weight management, semaglutide is approved to reduce the risk of major cardiovascular events, including heart attack and stroke, in adults with established heart disease who are also classified as having obesity or overweight.

Important Considerations

This medication is intended for long-term use as part of a comprehensive lifestyle plan. It is not intended for short-term or cosmetic weight loss. The FDA has issued warnings regarding the use of unapproved or compounded versions of the drug, which may not meet safety and quality standards.